Golden Years Home Care Continues to Enhance Senior Living with Premier Home Help Care Services in El Dorado Hills, CA
Golden Years Home Care reaffirms its dedication to enhancing senior living with premier home help care services in El Dorado Hills, CA. Through personalized care plans, compassionate companionship, and assistance with daily activities, the agency empowers seniors to age comfortably and independently at home. Families gain peace of mind knowing rigorously trained caregivers provide dignified, reliable support rooted in respect, empathy, and a commitment to improving quality of life.
El Dorado Hills, CA - Golden Years Home Care, a leading local provider of senior care, today reaffirmed its ongoing commitment to enhancing the lives of seniors through its specialized and compassionate support systems. The organization is bolstering its renowned home help care services in El Dorado Hills, CA, to ensure families and their aging loved ones continue to have access to the highest standard of dignified, in-home assistance.
A primary benefit of the services provided by Golden Years Home Care is the profound impact on a senior's independence and quality of life. By enabling seniors to age gracefully within the comfort and familiarity of their own homes, the agency fosters a sense of autonomy and well-being. Care plans are highly personalized to meet the unique needs of each client, encompassing everything from assistance with daily activities and personal care to providing essential companionship, thereby alleviating feelings of loneliness and isolation that can often affect the elderly.
Furthermore, Golden Years Home Care provides invaluable peace of mind for families. Entrusting the care of a loved one to an outside provider requires a significant level of confidence, and the agency builds this trust through its unwavering reliability and the professional compassion of its caregivers. As a top-tier home help care agency in El Dorado Hills, CA, it ensures that all caregivers are not only rigorously trained and vetted but also share the company's core values of respect and empathy, allowing family members to rest assured that their loved one is in safe and caring hands.
"Our mission has always been rooted in compassion and respect for the individuals we serve," said Ken Ballard, founder of Golden Years Home Care. "We believe that every senior deserves to live their later years with dignity, comfort, and joy. It is our privilege to be welcomed into our clients' homes and to become a trusted extension of their family, providing the support that makes a meaningful difference every single day."
The growing need for reliable senior care highlights the importance of an agency that operates with integrity and a client-first philosophy. Golden Years Home Care was founded on the principle that exceptional care is both a service and a calling. This belief drives the agency's commitment to ensuring every senior feels respected, valued, and understood, solidifying its role as a cornerstone of dignified senior support within the El Dorado Hills community.
Golden Years Home Care is dedicated to helping families find the perfect care solution that fits their specific circumstances. By offering flexible and comprehensive support, the agency empowers seniors to live more safely, comfortably, and happily at home.
For more information about Golden Years Home Care and its home help services in El Dorado Hills, CA, or to schedule a complimentary consultation, please visit their website at https://goldenyearshomecare.com/sacramento-ca.
About Golden Years Home Care:
Golden Years Home Care is a premier provider of in-home care serving seniors in El Dorado Hills, CA, and the surrounding areas. Founded on the principles of compassion, dignity, and respect, the agency is dedicated to helping clients maintain their independence and quality of life in the comfort of their own homes. Their team of professional and empathetic caregivers specializes in a range of services, including personal care, companionship, and assistance with daily living, all tailored to meet the unique needs of each individual and their family.
Media Contact
Company Name: Golden Years Home Care (Sacramento, CA)
Contact Person: Ken Ballard
Email: Send Email
Phone: (916) 333-0383
Address: 717 K St #211
City: Sacramento
State: California 95814
Country: United States
Website: https://goldenyearshomecare.com/sacramento-ca/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
Migraine Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
DelveInsight's, 'Migraine Pipeline Insight 2025' report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Migraine Treatment Landscape. Click here to read more @ Migraine Pipeline Outlook Key Takeaways from the Migraine Pipeline Report On 17 August 2025, Teva Branded Pharmaceutical Products R&D LLC announced a study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). On 15 August 2025, Pfizer conducted a study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. On 15 August 2025, AbbVie announced a study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort) DelveInsight's Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment. The leading Migraine Companies such as Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Promising Migraine Pipeline Therapies such as ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others. Stay informed about the cutting-edge advancements in Migraine Treatments. Download for updates and be a part of the revolution in Neurology care @ Migraine Clinical Trials Assessment Migraine Emerging Drugs Profile AXS-07: Axsome Therapeutics AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development. STS-101: Satsuma Pharmaceuticals STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. TS101 has a number of key advantages that we believe may provide significant benefits over other acute treatments for migraine and result in robust and consistent clinical performance. These advantages arise from our proprietary dry-powder formulation, which incorporates a mucoadhesive drug carrier and engineered drug particle technologies, and our proprietary nasal delivery device. STS101 is an investigational product that is currently being evaluated in Phase 3 clinical trials for the acute treatment of migraine and is not approved by the U.S. Food and Drug Administration. Zavegepant: Biohaven Pharmaceuticals Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals. TNX1900: Tonix Pharmaceuticals TNX-1900(Oxytocin), Tonix's proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic migraine. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. In clinical and preliminary research, it has been observed that increased oxytocin levels can relieve headaches. When oxytocin is delivered via the nasal route, it results in enhanced binding to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals. Intranasal oxytocin has been well tolerated in several clinical trials in adults and children and has been shown to block calcitonin gene-related peptide (CGRP) release in animals, a pathway known to be critical to the pathogenesis of migraine attacks. TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. TNX-1900 is an investigational new drug and has not been approved for any indication. The Migraine pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment. Migraine Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market. Get a detailed analysis of the latest innovations in the Migraine pipeline. Explore DelveInsight's expert-driven report today! @ Migraine Unmet Needs Migraine Companies Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Migraine Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Discover the latest advancements in Migraine Treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Migraine Market Drivers and Barriers, and Future Perspectives Scope of the Migraine Pipeline Report Coverage- Global Migraine Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Migraine Pipeline Therapies- ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others. Migraine Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Migraine Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Migraine Pipeline on our website @ Migraine Emerging Drugs and Companies Table of Content Introduction Executive Summary Migraine: Overview Pipeline Therapeutics Therapeutic Assessment Migraine– DelveInsight's Analytical Perspective Late Stage Products (Pre-Registration) AXS-07: Axsome Therapeutics Drug profiles in the detailed report….. Last Stage Products (Phase III) STS-101: Satsuma Pharmaceuticals Drug profiles in the detailed report….. Mid Stage Products (Phase II) TNX1900: Tonix Pharmaceuticals Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company Name Drug profiles in the detailed report….. Inactive Products Migraine Key Companies Migraine Key Products Migraine - Unmet Needs Migraine - Market Drivers and Barriers Migraine - Future Perspectives and Conclusion Migraine Analyst Views Migraine Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
2 hours ago
- Globe and Mail
Influenza Pipeline Outlook 2025 – Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight
The Influenza pipeline is experiencing unprecedented growth, driven by 120+ active players, breakthrough therapies, and recent FDA fast-track designations, signaling a transformative decade ahead in Influenza treatment. Influenza Pipeline Summary DelveInsight's Influenza Emerging Drugs report highlights innovative therapies advancing the treatment and prevention of influenza. Key candidates include Moderna's mRNA-1010, a Phase III vaccine encoding HA glycoproteins of WHO-recommended strains; SAB Biotherapeutics' SAB-176, a quadrivalent, broadly neutralizing polyclonal antibody for severe influenza; ENA Respiratory's INNA-051, an immunomodulatory intranasal spray in Phase IIa; Codagenix's CODA-VAX H1N1, a universal live-attenuated flu vaccine in Phase I; and AlloVir's ALVR106, an allogeneic, off-the-shelf VST therapy targeting multiple respiratory viruses. The report further analyzes over 120+ pipeline drugs across various clinical stages, including Phase III, II, I, preclinical, and discovery. It categorizes therapies by route of administration (oral, intravenous, intranasal, inhalation, subcutaneous, etc.), molecule type (antibodies, vaccines, peptides, proteins, immunotherapies, small molecules, stem cells), and product type (mono, combination, or both). Moderna currently leads the late-stage pipeline, showcasing the growing diversity and innovation in influenza treatment strategies. Key Takeaways from the Influenza Pipeline Report Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment. In August 2025, AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination. AstraZeneca launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST®(Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. In July 2025, SK bioscience, a global innovative vaccine and biotech company dedicated to advancing human health from prevention to cure, announced that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. This candidate integrates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu', to improve protective efficacy. SK bioscience previously applied adjuvant technology in its COVID-19 vaccine, 'SKYCovione', and now aims to extend this approach to influenza vaccines as part of its broader platform strategy. In July 2025, GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. In March 2025, Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. In December 2024:- ModernaTX, Inc.- A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age. The purpose the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea). In November 2024:- DiaSorin Molecular LLC- The DiaSorin Molecular LIAISON® NES FLU A/B, RSV & COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. In October 2024:- Pfizer- The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine. The leading Influenza Companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Promising Influenza Therapies such as OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others. Stay ahead with the most recent pipeline outlook for Influenza. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Influenza Treatment Drugs Influenza Emerging Drugs · mRNA-1010 (Moderna): A Phase III vaccine targeting WHO-recommended influenza strains (A/H1N1, A/H3N2, B/Yamagata, B/Victoria). Encodes HA glycoproteins to generate broad protection against seasonal influenza. · SAB-176 (SAB Biotherapeutics): A quadrivalent polyclonal antibody therapy developed via DiversitAb™ platform. Designed to neutralize Type A and B influenza viruses, showing broad protection potential. Targeted for severe cases and high-risk groups like elderly and immunocompromised patients. · INNA-051 (ENA Respiratory): An intranasal immunomodulatory spray in Phase IIa trials. Intended for pre- and post-exposure prophylaxis of respiratory viral infections, with potential use across multiple viruses and at-risk populations. · CODA-VAX H1N1 (Codagenix): A live-attenuated universal flu vaccine in Phase I trials. Shows promise for multi-season protection by targeting conserved viral antigens and is being developed into a quadrivalent formulation. · ALVR106 (AlloVir): An allogeneic, off-the-shelf VST therapy in preclinical development. Targets RSV, influenza, PIV, and hMPV, with in vitro data showing strong antiviral activity and potential safety benefits. Explore groundbreaking therapies and clinical trials in the Influenza Pipeline. Access DelveInsight's detailed report now! @ New Influenza Drugs Key influenza Companies: The following are the leading companies in the influenza market. These companies collectively hold the largest market share and dictate industry trends. Influenza Pipeline Drugs by Route of Administration Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous • Intravenous/ Subcutaneous • NA • Oral • Oral/intranasal/subcutaneous • Parenteral • Subcutaneous Influenza Pipeline Drugs by Molecule Types Influenza Products have been categorized under various Molecule types such as • Antibody • Antisense oligonucleotides • Immunotherapy • Monoclonal antibody • Peptides • Protein • Recombinant protein • Small molecule • Stem Cell • Vaccine Unveil the future of Influenza Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Influenza Market Drivers and Barriers Scope of the Influenza Pipeline Report Coverage- Global Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Influenza Therapies- OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Table of Content 1. Influenza Report Introduction 2. Influenza Executive Summary 3. Influenza Overview 4. Influenza- Analytical Perspective In-depth Commercial Assessment 5. Influenza Pipeline Therapeutics 6. Influenza Late Stage Products (Phase II/III) 7. Influenza Mid Stage Products (Phase II) 8. Influenza Early Stage Products (Phase I) 9. Influenza Preclinical Stage Products 10. Influenza Therapeutics Assessment 11. Influenza Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Influenza Key Companies 14. Influenza Key Products 15. Influenza Unmet Needs 16 . Influenza Market Drivers and Barriers 17. Influenza Future Perspectives and Conclusion 18. Influenza Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Toronto Sun
4 hours ago
- Toronto Sun
More frozen shrimp recalled for possible radioactive contamination
Published Aug 21, 2025 • 1 minute read Photo by Getty Images More packages of frozen shrimp potentially affected by radioactive contamination have been recalled, federal officials said Thursday. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account California-based Southwind Foods recalled frozen shrimp sold under the brands Sand Bar, Arctic Shores, Best Yet, Great American and First Street. The bagged products were distributed between July 17 and Aug. 8 to stores and wholesalers in nine states: Alabama, Arizona, California, Massachusetts, Minnesota, Pennsylvania, Utah, Virginia, and Washington state. The products have the potential to be contaminated with Cesium-137, a radioactive isotope that is a byproduct of nuclear reactions. Walmart stores this week recalled packages of Great Value frozen raw shrimp sold in 13 states because of potential radioactive contamination. The U.S. Food and Drug Administration issued a safety alert after federal officials detected Cesium-137 in shipping containers sent to four U.S. ports and in a sample of frozen breaded shrimp imported by BMS Foods of Indonesia. The FDA advises consumers not to eat the recalled products. Traces of Cesium-137 are widespread in the environment including food, soil and air. The primary health risk is through long-term, repeated low-dose exposure, which can increase the risk of cancer. Toronto & GTA Columnists World Columnists Canada
